Completion of enrollment in February with 390 total subjects in the company's pivotal Phase 3 trial of Allovectin-7?® in patients with metastatic melanoma; Enhanced cellular and antibody immune responses for the company's TransVax?„? cytomegalovirus (CMV) vaccine vs placebo through the final 12-month immunogenicity data point in the ongoing Phase 2 trial in hematopoietic cell transplant (HCT) recipients; Initiation of a Phase 1 clinical trial of the company's vaccine against H1N1 pandemic influenza with U.S. Navy funding; The launch by the company's licensee Merial Limited, the animal health subsidiary of sanofi-aventis, of its ONCEPT?„? canine melanoma vaccine, a therapeutic DNA vaccine designed to aid in extending survival of dogs with oral melanoma; Presentation of encouraging results from a Phase 1/2a clinical trial of a prime-boost vaccine regimen and publication of preclinical data demonstrating enhancement of immune responses with the company's Vaxfectin?® adjuvant, both in collaboration with the U.S. military on DNA vaccines for malaria; and Publication of Phase 1 results highlighting safety and tolerability, antibody responses in the same range as conventional vaccines, sustained immunogenicity, and cross-clade antibody responses for the company's H5N1 pandemic influenza vaccine.

Anticipated program highlights for the remainder of 2010 include:

Results of independent safety monitoring board review of the company's Phase 3 trial of Allovectin-7?® in patients with metastatic melanoma; Final results in the third quarter of 2010 from the Phase 2 trial of the company's TransVax?„? CMV vaccine candidate for HCT patients; Immunogenicity data from a Phase 1 trial of the company's Vaxfectin?®-adjuvanted DNA vaccine for H1N1 influenza; and Data in the fourth quarter of 2010 from the company's licensee, sanofi aventis Group, from the ongoing TAMARIS Phase 3 trial of Temusi?®, intended to promote the growth of blood vessels to reduce the need for amputations in patients with reduced blood flow to the limbs.

SOURCE Vical Incorporated